Vivimed Labs Limited share price

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India. It operates through two segments, Speciality Chemicals Business and Pharma Business. The company provides APIs and intermediates to generic and ethical companies; and branded formulations in therapeutic segments, such as ophthalmic, nutraceuticals, dermatology, and pain, as well as contract manufacturing of capsules and tablets, syrups and liquids, and nasal sprays and ointments. It also exports its products. The company was incorporated in 1988 and is based in Hyderabad, India.Read more

Website NSE हिंदी में BSE

HealthcareDrug Manufacturers - Specialty & GenericNSE: VIVIMEDLABISIN INE526G01021

16 Oct 2026, 12:42 PM IST₹6.58▼ 0.13 (1.94%)

Market Cap₹ 55 Cr.
Current Price₹ 6.58
High / Low₹ 29 / 5
Stock P/E—
Book Value₹ -25
Dividend Yield0.00 %
ROCE-56.4 %
ROE143.60 %
Face Value₹ 10.0

More figures (10)

EPS (TTM)₹ -21.13
Price / Book—
OPM-255.0 %
Debt / Equity-1.89
Sales growth (5Y)-39.5 %
Profit growth (5Y)—
Promoter holding14.9 %
EV / EBITDA-3.1
Beta0.84
All-time high₹ 249

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
VIVIMEDLAB	+13.45%	+29.53%	-10.96%	-62.76%	+32.93%	+9.95%	-20.88%
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

Vivimed Labs Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹55 crore.
Revenue grew -39.5% a year over the last 5 years.
Return on equity was 143.6% and return on capital employed -56.4% in the latest year.
Debt was -1.89 times shareholders' equity.
The share price is 77.6% below its 52-week high and up 32.9% over one year.
Promoters and insiders hold about 14.9%; institutions about 9.4%.

Pros

Company is almost debt-free (debt is -1.89 times equity).

Cons

Sales growth has been slow: -39.5% a year over the last 5 years.
Promoter holding has fallen by 13.37 points over 3 years, to 7.57%.
The company has not paid a dividend recently.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Vivimed Labs Limited

Head office: Hyderabad

HealthcareDrug Manufacturers - Specialty & Generic

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	Vivimed Labs	6.58	—	55	0.00	-146	—	12	-53.15	-56.4	143.6	-0.26	-255.0	-1.89	14.92	70	-39.5
2.	Sun Pharmaceutical Industries	1,758.80	34.9	4,21,995	0.91	2,895	34.65	15,184	18.48	17.9	14.7	5.05	23.4	0.06	55.61	58,220	10.4
3.	Divi's Laboratories	9,144.50	83.0	2,42,758	0.33	902	36.25	3,080	19.15	19.0	16.2	14.48	28.4	0.00	52.00	10,476	11.0
4.	Torrent Pharmaceuticals	4,558.90	72.8	1,73,406	0.83	566	3.28	4,921	54.85	9.1	27.1	18.39	25.0	1.79	63.18	13,980	13.3
5.	Zydus Lifesciences	1,123.00	25.0	1,12,020	0.09	940	-19.74	7,802	24.03	19.0	19.7	4.17	21.7	0.46	75.18	26,720	16.5
6.	Laurus Labs	2,060.10	101.8	1,11,310	0.12	362	123.94	2,026	29.10	19.5	18.2	20.98	19.4	0.48	32.03	6,813	3.8
7.	Cipla	1,325.10	31.8	1,07,051	0.98	786	-39.18	7,119	2.33	14.9	11.8	3.11	17.5	0.02	31.13	28,163	7.2
8.	Dr. Reddy's Laboratories	1,233.00	31.0	1,02,707	0.66	444	-68.72	8,071	-5.56	14.2	12.1	2.68	14.9	0.21	30.14	33,593	11.0
9.	Aurobindo Pharma	1,666.90	26.0	95,910	0.00	1,033	14.29	9,106	8.65	13.5	9.9	2.56	15.6	0.21	54.79	33,385	10.7
10.	Mankind Pharma	2,275.50	46.0	93,988	0.00	574	29.12	4,031	12.89	13.7	12.5	5.76	19.9	0.39	75.39	14,278	17.7
	Median: 53 Co.	1,712.85	31.8	14,896	0.31	680	14.29	6,020	15.68	14.6	13.5	4.01	15.6	0.21	53.40	20,499	11.0

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Consolidated figures in ₹ crore /

₹ Cr	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	37	35	34	41	39	29	25	37	26	21	21	16	12
YOY Sales Growth %	-39.43%	-29.45%	-23.93%	-25.62%	4.28%	-16.91%	-26.37%	-11.94%	-33.67%	-27.18%	-16.79%	-56.21%	-53.15%
	201	36	40	40	67	33	25	35	33	22	22	27	151
Material Cost %	492%	51%	53%	52%	36%	59%	46%	54%	45%	46%	44%	49%	391%
Employee Cost %	24%	22%	29%	24%	18%	21%	25%	20%	34%	27%	27%	23%	83%
Other Expenses %	28%	28%	36%	21%	120%	34%	31%	23%	29%	29%	33%	96%	786%
Operating Profit	-164	-0	-6	1	-28	-4	-1	1	-7	-0	-1	-11	-139
OPM %	-444%	-1%	-18%	3%	-74%	-13%	-3%	3%	-29%	-1%	-5%	-68%	-1,160%
Other Income	1	0	2	0	8	0	0	0	4	0	0		6
Interest	9	11	12	13	-33	0	0	0	2	1	2	1	1
Depreciation	96	5	5	5	6	4	4	7		5	5	5	12
Profit before tax	-268	-16	-20	-17	7	-8	-5	-6	-5	-5	-7	-17	-146
					21%
Current tax					0				0				0
Deferred tax	-2			-1	1				-0				0
	-266	-16	-20	-16	5	-8	-5	-6		-5	-7	-17	-146
Profit to shareholders	-265
EPS in Rs	-1.28	0.08	-0.10	-0.05	0.03	-0.04	-0.02	-0.14	-0.13	-0.66	-0.88	-0.88	-17.74
Raw filing

₹ Cr	Mar 2026
Sales	8
	144
Material Cost %	608%
Employee Cost %	114%
Other Expenses %	1,181%
Operating Profit	-136
OPM %	-1,803%
Other Income	0
Interest	1
Depreciation	4
Profit before tax	-141
Net Profit	-141
EPS in Rs	-17.14
Raw filing

Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ Cr	Mar 2018	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	1,186	1,059	861	237	187	149	116	70
YOY Sales Growth %		-10.70%	-18.64%	-72.46%	-21.15%	-20.33%	-22.00%	-39.80%
	974	1,051	838	245	374	182	149	221
Material Cost %	40%	44%	41%	65%	145%	48%	51%	105%
Employee Cost %	17%	22%	23%	15%	17%	23%	24%	36%
Other Expenses %	25%	34%	33%	23%	38%	52%	35%	175%
Operating Profit	212	8	24	-8	-187	-33	-33	-151
OPM %	18%	1%	3%	-3%	-100%	-22%	-28%	-216%
Other Income	10	8	10	1	1	10	4	6
Interest	79	59	54	40	36	2	3	4
Depreciation	56	67	55	18	108	20		26
Profit before tax	86	-109	-76	-65	-331	-46	-31	-175
	11%
Current tax	12	4	3			0	0	0
Deferred tax	-3	-4	-1	3	-2	-0	-0	0
	78	-109	-78	-68	-329	-45		-175
Minority share	-2
Profit to shareholders					-328
YOY Profit Growth %		-239.99%
EPS in Rs	0.74	-0.53	-0.75	-0.33	-1.58	-0.22	-0.77	-21.15

Compounded Sales Growth

5 Years:: -39%
3 Years:: -28%

Stock Price CAGR

5 Years:: -21%
3 Years:: 10%
1 Year:: 33%

Return on Equity

4 Years:: -200%
Last Year:: 144%

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	261	252	277	210	218	177	137	104	56
YOY Sales Growth %		-3.66%	9.85%	-24.06%	3.96%	-19.02%	-22.64%	-24.26%	-46.16%
	185	185	244	188	228	365	170	136	205
Material Cost %	33%	32%	54%	46%	66%	152%	49%	56%	127%
Employee Cost %	13%	15%	12%	15%	15%	16%	22%	22%	37%
Other Expenses %	24%	26%	22%	28%	24%	38%	54%	35%	204%
Operating Profit	77	67	32	22	-9	-188	-34	-33	-149
OPM %	29%	27%	12%	10%	-4%	-106%	-25%	-31%	-267%
Other Income	2	9	7	6	1	0	10	4	1
Interest	52	52	43	41	40	35	2	3	4
Depreciation	18	18	17	16	17	107	18		18
Profit before tax	9	5	-21	-29	-65	-330	-44	-31	-171
	-11%	-21%
Current tax	2	1		-0
Deferred tax	-3	-2	-2		3	-2
	10	6	-19	-29	-68	-328	-44		-171
YOY Profit Growth %		-37.31%	-409.92%
EPS in Rs	2.40	0.75	-2.31	-7.10	-8.17	-39.56	-5.35	3.87	-20.59

Compounded Sales Growth

5 Years:: -23%
3 Years:: -32%

Stock Price CAGR

5 Years:: -21%
3 Years:: 10%
1 Year:: 33%

Return on Equity

4 Years:: -200%
Last Year:: 144%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	17	17	17	17
Reserves	23	-22	-52	-227
	381	379	376	397
Long term borrowings	62	64	64	72
Short term borrowings	316	313	313	326
	575	578	580	567
Trade payables	55	44	39	53
Current liabilities	424	410	408	448
Total Liabilities	995	951	921	753
	299	284	271	255
Gross block	580	581	586	255
Accumulated depreciation	281	298	315
Goodwill & intangibles	158	155	153
CWIP	21	21	17	18
	676	647	633	481
Inventories	80	64	59	13
Trade receivables	74	83	74	45
Cash & equivalents	4	2	1	1
Current assets	339	343	328	168
Total Assets	995	951	921	753

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	35	-24	-1	8
Profit for the year	-329	-45	-32	-176
Working capital changes	222	-15	7	153
Direct taxes paid		0	-0	-0
	-5	28	-5	-1
Fixed assets purchased	-5	-2	-5	-1
Investments sold		30
	-34	-6	4	-6
Interest paid	-36	-2	-3	-4
Net Cash Flow	-3	-2	-1	1
Free Cash Flow	30	-26	-6	7

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	—	-833.4%	-267.6%	157.3%	143.6%
ROCE	—	-51.8%	-8.3%	-5.6%	-56.4%
Operating margin	—	-109.9%	-13.8%	-28.6%	-255.0%
Net margin	—	-175.6%	-30.5%	-27.5%	-252.1%
Debt / equity	—	9.67	-69.36	-10.70	-1.89
Current ratio	—	0.80	0.83	0.80	0.37
Debtor days	—	145	203	233	236
Inventory days	—	104	302	358	63
Days payable	—	72	208	240	264
Cash conversion cycle	—	177	297	351	35
Working capital days	—	-166	-166	-253	-1,461

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 7.57%
FIIs 1.64%
Government 0.12%
Public 90.67%

%	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Promoters	20.94%	20.94%	20.94%	20.94%	20.94%	20.94%	20.94%	20.94%	7.77%	7.77%	7.77%	7.57%
	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%
Foreign portfolio investors (Cat. I)	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%
Government	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%
	77.30%	77.30%	77.30%	77.30%	77.30%	77.30%	77.30%	77.30%	90.48%	90.48%	90.48%	90.67%
Retail (up to ₹2 lakh)	51.82%	51.20%	51.19%	51.13%	51.13%	51.13%	51.20%	51.15%	57.46%	57.45%	57.34%	57.49%
HNIs (above ₹2 lakh)	5.18%	5.51%	5.51%	6.10%	6.10%	6.10%	6.10%	6.77%	7.73%	7.72%	7.72%	11.26%
NRIs	4.42%	4.50%	4.52%	4.59%	4.60%	4.60%	4.53%	4.53%	4.53%	4.55%	4.55%	4.40%
Bodies corporate	4.85%	5.05%	5.05%	4.44%	4.44%	4.44%	4.44%	3.79%	9.67%	9.67%	9.78%	6.43%
IEPF								0.03%	0.05%	0.05%	0.05%	0.05%
No. of Shareholders	49,503	49,038	49,027	49,016	49,012	49,003	49,005	48,957	48,928	48,925	49,221	47,492

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

None filed recently.

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Ex-dividend date: 19 Sep 2018
Latest quarter: 31 Mar 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

No recent coverage found.

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about Vivimed Labs Limited

What is the share price of Vivimed Labs Limited today?

Vivimed Labs Limited (VIVIMEDLAB) last traded at ₹6.58 on NSE (16 Oct 2026, 12:42 PM IST). Prices may be delayed.

What is the market cap of Vivimed Labs Limited?

About ₹55 crore at the latest price.

What is the P/E ratio of Vivimed Labs Limited?

The P/E is not available (for example when earnings are negative).

Is Vivimed Labs Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy Vivimed Labs Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.

Vivimed Labs Limited share price

Price chart

Quick take

Pros

Cons

AI analysis

About Vivimed Labs Limited

Peer comparison

Quarterly Results

Profit & Loss

Projection — your assumptions

Related party transactions

Compounded Sales Growth

Stock Price CAGR

Return on Equity

Compounded Sales Growth

Stock Price CAGR

Return on Equity

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings

Concalls & investor meets

Key dates

Trade with our broking desk

Latest news

In the news

From the company (NSE)

Questions about Vivimed Labs Limited

Have a question about this topic?

Book your free wealth consultation

Request received!

What happens next